Seegene

Seegene Enterprise Value

The Enterprise Value (EV) of Seegene (096530.KQ) as of Oct 28, 2026 is 1.05 T KRW. In the previous year, Enterprise Value (EV) was 1.05 T KRW — a change of -0.05% (lower).

Enterprise Value

1.05 TKRW

YoY

-0.05%

Last updated:

Enterprise Value (EV) of Seegene is 2025 1.05 T KRW. Enterprise Value (EV) of Seegene was 2024 1.05 T KRW. It decreases by -0.05% lower compared to the previous year.

The Seegene Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
1.02 T KRW
Jan 1, 2019
1.00 T KRW
Jan 1, 2020
835.45 B KRW
Jan 1, 2021
739.28 B KRW
Jan 1, 2022
609.08 B KRW
Jan 1, 2023
1.06 T KRW
Jan 1, 2024
1.05 T KRW
Jan 1, 2025
1.05 T KRW
The Seegene Enterprise Value history
YEAREnterprise ValueYoY
1.05 TKRW-0.05%
1.05 TKRW-0.06%
1.06 TKRW+73.23%
609.08 BKRW-17.61%
739.28 BKRW-11.51%
835.45 BKRW-16.68%
1.00 TKRW-1.68%
1.02 TKRW-1.06%
1.03 TKRW+1.08%
1.02 TKRW-0.29%
1.02 TKRW-5.69%
1.08 TKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

Enterprise Value (EV) of Seegene is 1.05 T KRW in 2025.

Enterprise Value (EV) of Seegene changed from 1.05 T KRW to 1.05 T KRW, representing a -0.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Seegene since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s KRW, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' KRW varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Seegene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Seegene

All Key Metrics — Seegene